PSI-697

Phase 1Small molecule

Pfizer

PSI-697 is one of 7 small molecule programs targeting Scleritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScleritisActive, not recruiting

ScleritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Scleritis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

—2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 3

Rituxan

Roche

Phase 2

1 4

Remicade

OOrganon and Co

Phase 1

2 5

Rapamune

PPrism Pharmaceuticals

Phase 1

1 6

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 1

1 7

PSI-697

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Scleritis1 trial

Study Evaluating PSI-697 in Patients With Scleritis

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00367692·12 enrolled

Unspecified1 trial

Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke

Completed· Pfizer logo

Pfizer·Phase 1·NCT03860506·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PSI-697. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PSI-697 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PSI-697. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PSI-697

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Scleritis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News